VELOXIS PHARMACEUTICALS A/S: Financial statements 2017
CVR: 26527767
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
VELOXIS PHARMACEUTICALS A/S (CVR 26527767) has filed annual accounts for 2017. In 2017, the company reported revenue of USD 30,167,000 and a net result of USD -9,542,000 compared with USD -10,135,000 the year before. That is an increase of 228.1% compared with the year before. The profit margin was -31.6%. Equity in the 2017 report amounted to USD 5,316,000. The solvency ratio was 12.7%.
- Revenue
- USD 30,167,000
- Gross Profit
- USD 24,965,000
- Profit/Loss
- USD -9,542,000
- Equity
- USD 5,316,000
- Total Assets
- USD 41,921,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | 30.2M USD | 25M USD | -9.5M USD | 5.3M USD | - |
| 2016 | 9.2M USD | 6.2M USD | -10.1M USD | 10.2M USD | - |
| 2015 | 14.2M | -989K | -176.1M | 89.7M | - |
| 2014 | 123.4M | 120.1M | -36.3M | 253.2M | - |
Official annual report
Keep an eye on VELOXIS PHARMACEUTICALS A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2017 to September 30, 2017.
As of September 20, 2017, Alastair Stuart McEwan has stepped down as director of VELOXIS PHARMACEUTICALS A/S.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2017 to June 30, 2017.
VELOXIS PHARMACEUTICALS A/S has published its interim report for the period January 1, 2017 to March 31, 2017.
VELOXIS PHARMACEUTICALS A/S has published its annual report for 2016. Revenue came to DKK 9,194,000, and the net result was DKK -10,135,000.
About VELOXIS PHARMACEUTICALS A/S
VELOXIS PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Nordhavn, founded in 2002. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named LIFECYCLE PHARMA A/S and PHAROTECH A/S. The management consists of Daisuke Matsuo. The board consists of Keigo Nakatsukasa (chair), Daisuke Matsuo and Kenro Yuzaki. The company is owned by Asahi Kasei Corporation. The company has 1 employee (2022). In 2026, the company reported a net result of DKK -1,553,000. Equity in the 2026 report amounted to DKK 611,587,000.